BenevolentAI

The company's proprietary AI-enabled drug discovery platform, the Benevolent Platform, enables computational R&D. It is disease agnostic and is capable of rapidly generating novel targets at scale.

In October 2022, the UK-based company announced that one of its collaboration partners, AstraZeneca, had selected an additional two novel targets to enter its drug portfolio, resulting in two milestone payments to BenevolentAI.

Latest BenevolentAI News & Features